talazoparib
Researchers say the rare subtype of gamma-delta T-ALL, characterized by the STAG2/LMO2 rearrangement, may be vulnerable to this class of drugs.
Chinese Trial Suggests PARP, VEGF Inhibitor Combo Benefits Advanced BRCA1/2-Mutant Breast Cancer
Premium
Fuzuloparib, both alone and combined with apatinib, improved patients' progression-free survival versus standard chemotherapy.
NICE Recommends Pfizer's Talzenna for BRCA-Mutant, HER2-Negative Breast Cancer After Discount
NICE reversed its prior decision to not recommend Talzenna due to limited cost-effectiveness after Pfizer offered a confidential discount to the NHS.
Pfizer Oncology Revenues Fall 4 Percent in Q2; Officials Highlight Encouraging Data From Trials
Executives said the firm's acquisition of Seagen and advancement of new breast cancer candidates will help refocus its efforts in oncology.
FDA Approves Pfizer's Talzenna, Xtandi for HRR-Mutant Advanced Prostate Cancer
Pfizer initially sought approval for the combination in an all-comer population, but regulators have indicated the drug for a narrower, biomarker-defined group.
May 2, 2023
Sep 15, 2020